-
1
-
-
1842413105
-
The Non-Hodgkin's Lymphoma Classification Project
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-3918.
-
(1997)
Blood
, vol.89
, pp. 3909-3918
-
-
-
2
-
-
79958261904
-
The microenvironment in follicular lymphoma
-
de Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24:135-146.
-
(2011)
Best Pract Res Clin Haematol
, vol.24
, pp. 135-146
-
-
De Jong, D.1
Fest, T.2
-
3
-
-
0345337254
-
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
-
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-Lopez, A.J.2
Link, B.K.3
-
4
-
-
34249939116
-
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study
-
Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25:1986-1992.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1986-1992
-
-
Herold, M.1
Haas, A.2
Srock, S.3
-
5
-
-
53749085410
-
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
-
Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579-4586.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4579-4586
-
-
Marcus, R.1
Imrie, K.2
Solal-Celigny, P.3
-
6
-
-
28544435078
-
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
-
Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-3732.
-
(2005)
Blood
, vol.106
, pp. 3725-3732
-
-
Hiddemann, W.1
Kneba, M.2
Dreyling, M.3
-
7
-
-
58149386408
-
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study
-
Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824-4831.
-
(2008)
Blood
, vol.112
, pp. 4824-4831
-
-
Salles, G.1
Mounier, N.2
De Guibert, S.3
-
8
-
-
78650823247
-
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial
-
Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377:42-51.
-
(2011)
Lancet
, vol.377
, pp. 42-51
-
-
Salles, G.1
Seymour, J.F.2
Offner, F.3
-
9
-
-
0021703548
-
The natural history of initially untreated low-grade non-Hodgkin's lymphomas
-
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471-1475.
-
(1984)
N Engl J Med
, vol.311
, pp. 1471-1475
-
-
Horning, S.J.1
Rosenberg, S.A.2
-
10
-
-
0023992626
-
The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment
-
Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25 (2 Suppl 2):11-16.
-
(1988)
Semin Hematol
, vol.25
, Issue.2 SUPPL. 2
, pp. 11-16
-
-
Young, R.C.1
Longo, D.L.2
Glatstein, E.3
-
11
-
-
0031050192
-
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte
-
Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15:1110-1117.
-
(1997)
J Clin Oncol
, vol.15
, pp. 1110-1117
-
-
Brice, P.1
Bastion, Y.2
Lepage, E.3
-
12
-
-
0041656437
-
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: A randomised controlled trial
-
Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362:516-522.
-
(2003)
Lancet
, vol.362
, pp. 516-522
-
-
Ardeshna, K.M.1
Smith, P.2
Norton, A.3
-
13
-
-
0035169514
-
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
-
Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
-
(2001)
Blood
, vol.97
, pp. 101-106
-
-
Colombat, P.1
Salles, G.2
Brousse, N.3
-
14
-
-
78951481506
-
An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, nonbulky follicular lymphoma (Grades 1, 2 and 3a) A preliminary analysis
-
Ardeshna K, Qian W, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, nonbulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis. Blood 2010; 116:6.
-
(2010)
Blood
, vol.116
, pp. 6
-
-
Ardeshna, K.1
Qian, W.2
Smith, P.3
-
15
-
-
62449324950
-
Follicular lymphoma in the United States: First report of the national Lympho Care study
-
Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national Lympho Care study. J Clin Oncol 2009; 27:1202-1208.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1202-1208
-
-
Friedberg, J.W.1
Taylor, M.D.2
Cerhan, J.R.3
-
16
-
-
34249704600
-
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
-
Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706-714.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 706-714
-
-
Schulz, H.1
Bohlius, J.F.2
Trelle, S.3
-
17
-
-
77649225344
-
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: Effect of response quality on survival-A study from the groupe d'etude des lymphomes de l'adulte
-
Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 2010; 28:822-829.
-
(2010)
J Clin Oncol
, vol.28
, pp. 822-829
-
-
Bachy, E.1
Brice, P.2
Delarue, R.3
-
18
-
-
43249117980
-
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage
-
Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111:4004-4013.
-
(2008)
Blood
, vol.111
, pp. 4004-4013
-
-
Ladetto, M.1
De Marco, F.2
Benedetti, F.3
-
19
-
-
77951453410
-
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study
-
Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2011; 115:3215-3223.
-
(2011)
Blood
, vol.115
, pp. 3215-3223
-
-
Pott, C.1
Hoster, E.2
Delfau-Larue, M.H.3
-
20
-
-
38349119981
-
Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
-
Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26:204-210.
-
(2008)
J Clin Oncol
, vol.26
, pp. 204-210
-
-
Friedberg, J.W.1
Cohen, P.2
Chen, L.3
-
21
-
-
74549225036
-
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a Multicenter Study
-
Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2011; 116:106-114.
-
(2011)
Cancer
, vol.116
, pp. 106-114
-
-
Kahl, B.S.1
Bartlett, N.L.2
Leonard, J.P.3
-
22
-
-
20644469242
-
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
-
Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-3389.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3383-3389
-
-
Rummel, M.J.1
Al-Batran, S.E.2
Kim, S.Z.3
-
23
-
-
77950488976
-
Bendamustine plus rituximab is superior in respect of progression free survival and complete remission rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced Follicular, indolent, and Mantle Cell Lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)
-
abstract405
-
Rummel JR, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and complete remission rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced Follicular, indolent, and Mantle Cell Lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114:abstract405.
-
(2009)
Blood
, vol.114
-
-
Rummel, J.R.1
Niederle, N.2
Maschmeyer, G.3
-
24
-
-
0033625248
-
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809
-
Fisher RI, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18:2010-2016.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2010-2016
-
-
Fisher, R.I.1
Dana, B.W.2
Leblanc, M.3
-
25
-
-
0344157390
-
Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization
-
Arranz R, Garcia-Alfonso P, Sobrino P, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16:1538-1546.
-
(1998)
J Clin Oncol
, vol.16
, pp. 1538-1546
-
-
Arranz, R.1
Garcia-Alfonso, P.2
Sobrino, P.3
-
26
-
-
0007884202
-
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group
-
Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16:41-47.
-
(1998)
J Clin Oncol
, vol.16
, pp. 41-47
-
-
Hagenbeek, A.1
Carde, P.2
Meerwaldt, J.H.3
-
27
-
-
2942567554
-
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule
-
Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-4423.
-
(2004)
Blood
, vol.103
, pp. 4416-4423
-
-
Ghielmini, M.1
Schmitz, S.F.2
Cogliatti, S.B.3
-
28
-
-
14544276412
-
Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: A randomized phase II trial of the Minnie Pearl Cancer Research Network
-
Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1088-1095.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1088-1095
-
-
Hainsworth, J.D.1
Litchy, S.2
Shaffer, D.W.3
-
29
-
-
77956413908
-
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study
-
van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853-2858.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2853-2858
-
-
Van Oers, M.H.1
Van Glabbeke, M.2
Giurgea, L.3
-
30
-
-
83255176958
-
Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and metaanalysis of randomized trials
-
Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and metaanalysis of randomized trials. J Natl Cancer Inst 2011; 103:1799-1806.
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 1799-1806
-
-
Vidal, L.1
Gafter-Gvili, A.2
Salles, G.3
-
31
-
-
84867400613
-
Results of eastern cooperative oncology group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma
-
LBA-6
-
Kahl BS, Hong F, Williams ME, et al. Results of eastern cooperative oncology group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011; 118:LBA-6.
-
(2011)
Blood
, vol.118
-
-
Kahl, B.S.1
Hong, F.2
Williams, M.E.3
-
32
-
-
84855438011
-
Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia
-
Herold T, Seiler T, Egensperger R, et al. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 2011; 53:169-172.
-
(2011)
Leuk Lymphoma
, vol.53
, pp. 169-172
-
-
Herold, T.1
Seiler, T.2
Egensperger, R.3
-
33
-
-
27544508559
-
Tolerability and safety of rituximab (MabThera)
-
Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
-
(2005)
Cancer Treat Rev
, vol.31
, pp. 456-473
-
-
Kimby, E.1
-
34
-
-
0037306946
-
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
-
Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101:1045-1052.
-
(2003)
Blood
, vol.101
, pp. 1045-1052
-
-
Cragg, M.S.1
Morgan, S.M.2
Chan, H.T.3
-
35
-
-
84857327275
-
Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell Non-Hodgkin Lymphoma: Preliminary analysis of the GAUSS study
-
Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell Non-Hodgkin Lymphoma: preliminary analysis of the GAUSS study. Blood 2011; 118:269.
-
(2011)
Blood
, vol.118
, pp. 269
-
-
Sehn, L.H.1
Goy, A.2
Offner, F.C.3
-
36
-
-
79955979273
-
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies
-
Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies. Blood 2011; 117:4519-4529.
-
(2011)
Blood
, vol.117
, pp. 4519-4529
-
-
Alduaij, W.1
Ivanov, A.2
Honeychurch, J.3
-
37
-
-
77951561987
-
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
-
Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-4402.
-
(2010)
Blood
, vol.115
, pp. 4393-4402
-
-
Mossner, E.1
Brunker, P.2
Moser, S.3
-
38
-
-
78651354250
-
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
-
Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152:295-306.
-
(2011)
Br J Haematol
, vol.152
, pp. 295-306
-
-
Patz, M.1
Isaeva, P.2
Forcob, N.3
-
39
-
-
78751564397
-
Preclinical studies on the mechanism of action and the antilymphoma activity of the novel anti-CD20 antibody GA101
-
Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the antilymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10:178-185.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 178-185
-
-
Dalle, S.1
Reslan, L.2
Besseyre De Horts, T.3
-
40
-
-
84861835530
-
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
-
Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119:5126-5132.
-
(2012)
Blood
, vol.119
, pp. 5126-5132
-
-
Salles, G.1
Morschhauser, F.2
Lamy, T.3
-
41
-
-
79961240865
-
Promising efficacy with the new anti-CD20 antibody GA101 in heavily pretreated NHL patients: Updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL)
-
Salles GA, Morschhauser F, Thieblemont C, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pretreated NHL patients: updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL). Blood 2010; 116:2868.
-
(2010)
Blood
, vol.116
, pp. 2868
-
-
Salles, G.A.1
Morschhauser, F.2
Thieblemont, C.3
-
42
-
-
0031080328
-
CD22 is a negative regulator of B-cell receptor signalling
-
Nitschke L, Carsetti R, Ocker B, et al. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997; 7:133-143.
-
(1997)
Curr Biol
, vol.7
, pp. 133-143
-
-
Nitschke, L.1
Carsetti, R.2
Ocker, B.3
-
43
-
-
0042413843
-
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
-
Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3051-3059.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3051-3059
-
-
Leonard, J.P.1
Coleman, M.2
Ketas, J.C.3
-
44
-
-
33748471355
-
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
-
Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:3880-3886.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3880-3886
-
-
Strauss, S.J.1
Morschhauser, F.2
Rech, J.3
-
45
-
-
80054098574
-
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
-
Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011; 118:4053-4061.
-
(2011)
Blood
, vol.118
, pp. 4053-4061
-
-
Micallef, I.N.1
Maurer, M.J.2
Wiseman, G.A.3
-
46
-
-
67650346177
-
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
-
Rossi EA, Goldenberg DM, Cardillo TM, et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009; 113:6161-6171.
-
(2009)
Blood
, vol.113
, pp. 6161-6171
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Cardillo, T.M.3
-
47
-
-
41349118741
-
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action
-
Qu Z, Goldenberg DM, Cardillo TM, et al. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008; 111:2211-2219.
-
(2008)
Blood
, vol.111
, pp. 2211-2219
-
-
Qu, Z.1
Goldenberg, D.M.2
Cardillo, T.M.3
-
48
-
-
77957272703
-
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I/II study in non-Hodgkin's lymphoma
-
Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:3709-3716.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3709-3716
-
-
Morschhauser, F.1
Kraeber-Bodere, F.2
Wegener, W.A.3
-
49
-
-
77951648118
-
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase i study
-
Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28:2085-2093.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2085-2093
-
-
Advani, A.1
Coiffier, B.2
Czuczman, M.S.3
-
50
-
-
49649120397
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
-
Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-977.
-
(2008)
Science
, vol.321
, pp. 974-977
-
-
Bargou, R.1
Leo, E.2
Zugmaier, G.3
-
51
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115:2578-2585.
-
(2010)
Blood
, vol.115
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
-
52
-
-
78649797979
-
Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase i study
-
Advani R, Sharman JP, Smith SM, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J Clin Oncol 2010; 28 (15s):8012.
-
(2010)
J Clin Oncol
, vol.28
, Issue.15 S
, pp. 8012
-
-
Advani, R.1
Sharman, J.P.2
Smith, S.M.3
-
53
-
-
79958248822
-
Clinical activity in a phase 1 study of CAL-101 an isoform-selective inhibitor of phophatidylinositol 2-Kinase p110delta in patients with B-cell malignancies
-
Brown J, Byrd J, Furman R, et al. Clinical activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phophatidylinositol 2-Kinase p110delta, in patients with B-cell malignancies. Haematologica 2010; 95 (s2):466.
-
(2010)
Haematologica
, vol.95
, Issue.S2
, pp. 466
-
-
Brown, J.1
Byrd, J.2
Furman, R.3
-
54
-
-
51649123319
-
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximabtreated CD20+ tumor cells
-
Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximabtreated CD20+ tumor cells. Clin Cancer Res 2008; 14:4650-4657.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4650-4657
-
-
Wu, L.1
Adams, M.2
Carter, T.3
-
55
-
-
73949145763
-
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
-
Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27:5404-5409.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5404-5409
-
-
Witzig, T.E.1
Wiernik, P.H.2
Moore, T.3
-
56
-
-
79952947321
-
R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent Non-Hodgkin's Lymphoma (NHL)
-
abstract1679
-
Dutia M, DeRoock I, Chee K, et al. R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent Non-Hodgkin's Lymphoma (NHL). Blood 2009; 114:abstract1679.
-
(2009)
Blood
, pp. 114
-
-
Dutia, M.1
Deroock, I.2
Chee, K.3
-
57
-
-
79952853727
-
Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma
-
abstract8036
-
Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:abstract8036.
-
(2010)
J Clin Oncol
, vol.28
-
-
Fowler, N.H.1
McLaughlin, P.2
Hagemeister, F.B.3
|